Brand: 
NICE TA: 
Indication: Low dose prophylaxis of pneumocystis jirovecii (Pneumocystis carinii) infections post-transplant
Disease category: Infection
Commissioning responsibility: CCG
PbR excluded: No

Background

No regular routine monitoring will be required in primary care for the first 3 years of treatment. Patient monitoring will be carried out as part of tertiary care services at least monthly for the first year and every 6–12 weeks in year 2 post-transplant. For the limited number of patients still using prophylactic co-trimoxazole after 2 years post-transplant monitoring will be carried out in tertiary care services every 3–4 months in year 3.

Prophylactic co-trimoxazole treatment would not be expected to continue beyond 3 years for most patients. Where patients require prophylactic co-trimoxazole in years 4 and 5 post-transplant, consultants should liaise with primary care clinicians to ensure suitable blood monitoring arrangements are requested.

Recommendation

LMMG recommendation: Amber0
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

None

Decisions of Lancashire local decision making groups: